Daily BriefsEquity Bottom-Up

Daily Brief Equity Bottom-Up: Oriental Watch: Trading at 17% Yield and more

In today’s briefing:

  • Oriental Watch: Trading at 17% Yield, 60% Mkt Cap in Cash
  • Calbee – Price Hikes Are Appealing to Institutional Investors
  • Samsung C&T: Soundly Beat Consensus Operating Profit Estimates by 68% in 3Q 2022
  • CyberAgent 4Q: Gaming Deteriorates Further with Absence of New Hit Titles
  • Ultrajaya Milk Industry & Trading (ULTJ IJ) – The Raw Milk Dividend
  • Johnson Hitachi (JCHAC IN) | Losing Its “Cool”
  • CyberAgent (4751) | World Cup Boost for Abema
  • Sinotrans (598 HK): Showing Its Sustained Resilience
  • Spotify 3Q22: Another TikTok Victim?
  • Zhifei Biological Products (300122.CH) – More Downside Ahead, with Untenable Logic in HPV Vaccine

Oriental Watch: Trading at 17% Yield, 60% Mkt Cap in Cash

By Sameer Taneja

  • We remain cautious on Oriental Watch (398 HK) despite the recovery in sales in June this year. Wealth destruction in financial markets could impact sales in the short term.
  • Having said that, the stock is extremely cheap at 6.7x FY23 earnings (-32% YoY from FY22), with more than one bn HKD in cash (60% of market capitalization). 
  • With a generous payout ratio of >100%, the stock trades at >17% yield. We believe the company will dip into cash reserves to maintain a high yield.

Calbee – Price Hikes Are Appealing to Institutional Investors

By Oshadhi Kumarasiri

  • Japan’s largest snacks maker, Calbee Inc (2229 JP) is raising prices by 10-20% for almost 75% of its product range.
  • These price hikes have boded well with institutional investors with a vast most of them deciding to up their stake in the company following the first price hike announcement.
  • While institutional-investors bet on earnings growth over long-term through regular price revisions, we think there could also be short and medium-term gains as OP growth turns positive after many years.

Samsung C&T: Soundly Beat Consensus Operating Profit Estimates by 68% in 3Q 2022

By Douglas Kim

  • Samsung C&T had outstanding results that soundly beat consensus estimates in 3Q 2022.
  • Samsung C&T generated operating profit of 796.8 billion won in 3Q 2022, up 465% YoY and 67.7% higher than the consensus estimates. 
  • The strong growth of sales and operating profit was led by the biologics, construction, fashion, and resort businesses.

CyberAgent 4Q: Gaming Deteriorates Further with Absence of New Hit Titles

By Shifara Samsudeen, ACMA, CGMA

  • CyberAgent Inc (4751 JP) reported 4QFY09/22 financial results after the market closed on 26th. Revenue for the quarter decreased 1.9% YoY to JPY 176.2bn vs consensus revenue of JPY 175.5bn.
  • OP declined 50.8% YoY to JPY 13.2bn vs consensus JPY 16.0bn (miss of 9%) due to decline in profits from gaming business. OPM declined to 7.5% from 14.9% in 4QFY09/21.
  • CA’s earnings have come under pressure with absence of new hit game titles. Media segment continues to see strong growth and FIFA World Cup is only a one-off boost.

Ultrajaya Milk Industry & Trading (ULTJ IJ) – The Raw Milk Dividend

By Angus Mackintosh

  • Ultrajaya Milk Industry & Trading‘s last set of results reflected both the recovery in sales as mobility improved as well the pressure from rising packaging and imported milk powder prices.
  • Both whole milk powder and skimmed milk powder prices have declined by around 30% from the peak in April this year, which should help to underpin better margins in 2H2022. 
  • Ultrajaya Milk Industry & Trading has increased its advertising and promotional spending to take advantage of improved mobility, with strong growth momentum likely to persist in 2H2022 and into FY2023.

Johnson Hitachi (JCHAC IN) | Losing Its “Cool”

By Pranav Bhavsar

  • Our channel interactions continue to suggest, Johnson Controls-Hitachi Air Conditioning India (JCHAC IN) will not be able to recover market share over the next two years. 
  • More disappointment in line with what we have seen in Q2 remains a strong probability. 
  • Other annual report concerns also warrant attention, best to AVOID in spite of a sharp correction in stock price. 

CyberAgent (4751) | World Cup Boost for Abema

By Mark Chadwick

  • CyberAgent’s stock price could fall after releasing very weak guidance for the coming fiscal year
  • We would buy into any weakness as we see CyberAgent well placed to benefit from the structural growth of the Digital Ad market
  • We expect losses in ABEMA TV to shrink further next year and think the whole Media segment can break-even, driven by betting platform, Winticket

Sinotrans (598 HK): Showing Its Sustained Resilience

By Osbert Tang, CFA

  • Sinotrans (598 HK) delivered sustained healthy earnings in 3Q22, with reported profit rose 32.7% and recurring one up 13.2%. They are resilient given the adverse market environment.
  • Gross margin expansion and higher gross profit showed that lower freight rate has not had significant impact on profitability. DHL-Sinotrans’ contribution also recovered sequentially.
  • It cancelled the 0.62% of shares that it bought back, providing enhancement to forward EPS. The 9M22 result equals 91% of full-year consensus, suggesting room for earnings upgrade.

Spotify 3Q22: Another TikTok Victim?

By Aaron Gabin

  • MAUs beat, margins miss, guidance weak. Where / when is the operating leverage?
  • Podcasting business took a restructuring charge this quarter, not bullish for the business meant to expand gross margins.
  • TikTok reportedly readying a new streaming music app… not good.

Zhifei Biological Products (300122.CH) – More Downside Ahead, with Untenable Logic in HPV Vaccine

By Xinyao (Criss) Wang

  • Due to the lack of competitiveness, Zhifei’s self-developed products cannot contribute solid performance to make up for the shrinking revenue of HPV vaccines when more competing products gradually launched.
  • The real potential of HPV vaccine market in China is not as big as imagined. So, the companies involved have the problem of inflated market values.
  • Due to low demand of COVID-19 vaccine/negative impact of pandemic on HPV vaccination, Zhifei’s revenue YoY growth could be 10%-20%; Net profit YoY growth could be negative in 2022.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars